Search
Odevixibat
go.drugbank.com/drugs/DB16261ApprovedInvestigationalOdevixibat, or A4250, is an ileal sodium/bile acid cotransporter inhibitor indicated for the treatment of pruritus in patients older than 3 months, with progressive familial intrahepatic cholestasis (PFIC … [A236808] Odevixibat was granted FDA and Health Canada approval on 20 July 2021 and 13 November 2023 respectively.[L34793,L49535]
Categories: Bile and Liver Therapy, Alimentary Tract and MetabolismChymotrypsin
go.drugbank.com/drugs/DB09375ApprovedInvestigationalVet approvedWithdrawnChymotrypsin is the most abundant pancreatic proteases that represent up to 10-20% of the total protein synthesized by the exocrine pancreas [A32637]. … Like most proteolytic enzymes, chymotrypsin is activated from its inactive zymogen precursor, chymotrypsinogen, in presence of [DB11237].
Categories: Enzymes and Coenzymes, Blood and Blood Forming OrgansSulfur hexafluoride
go.drugbank.com/drugs/DB11104ApprovedInvestigationalSulfur hexafluoride is an ultrasound contrast agent indicated for use •in echocardiography to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border … in adult patients with suboptimal echocardiograms •in ultrasonography of the liver for characterization of focal liver lesions in adult and pediatric patients
Vosoritide
go.drugbank.com/drugs/DB11928ApprovedInvestigational[A242277] It results from a gain-of-function missense mutation in _FGFR3_ that results in a dramatic suppression of bone growth, both in volume and in length. … [L39229] It was approved for use under the brand name Voxzogo (BioMarin Pharmaceutical Inc.) in the EU in August 2021 and the US in November 2021,[L39245,L39241] becoming the first pharmacological intervention
Categories: Amino Acids, Peptides, and Proteins, Drugs Affecting Bone Structure and MineralizationChlamydial ophthalmia neonatorum
go.drugbank.com/conditions/DBCOND0020671Drugs: ErythromycinSynonyms: Neonatal conjunctivitis and dacryocystitisProctitis
go.drugbank.com/conditions/DBCOND0011080Drugs: Aluminum subacetate · Balsam of Peru · Calcium carbonate · Esculin · Fluocortolone caproate · Fluocortolone pivalate +7 moreSynonyms: Other specified diseases of anus and rectumRolapitant
go.drugbank.com/drugs/DB09291ApprovedInvestigationalBy blocking Substance P from interacting with NK-1 receptors in the gut and the central nervous system, rolapitant prevents late-phase CINV. … Unlike other available NK-1 receptor antagonists, rolapitant is not an inhibitor of Cytochrome P450 enzyme CYP3A4 and has a long elimination half-life, allowing a single dose to prevent both acute and
Categories: Antiemetics and Antinauseants, Alimentary Tract and MetabolismRivanicline
go.drugbank.com/drugs/DB05855ExperimentalRivanicline also has stimulant and analgesic actions which are thought due to increased noradrenaline release. … It was originally developed as a potential treatment for Alzheimer's disease for its nootropic effects but has also been found to inhibit the production of Interleukin-8.
Synonyms: (3E)-N-methyl-4-(pyridin-3-yl)but-3-en-1-amineTechnetium Tc-99m medronate
go.drugbank.com/drugs/DB09138ApprovedInvestigationalLike other bisphosphonates used in the treatment of osteoporosis, medronic acid binds to the hydroxyapatite crystals within bone, and in this way localizes the drug to bone for delineation of areas of … Following intravenous injection, single photon emission computed tomography (SPECT) is performed to detect the gamma ray emmitted by the decay of Technetium-99m to Technetium-99.
Synonyms: AN-MDPCategories: Indicators and ReagentsGemtuzumab ozogamicin
go.drugbank.com/drugs/DB00056ApprovedInvestigationalMarketing approval of gemtuzumab ozogamicin was granted on May 17, 2000 by FDA as a treatment for patients with CD33-positive AML in first relapse who are 60 years of age or older and who are not considered … However, it was voluntarily withdrawn from the market in 2010 due to safety concerns, increased patient deaths and insufficient evidence of clinical benefit during confirmatory trials [L941].
Categories: Amino Acids, Peptides, and Proteins, Antineoplastic and Immunomodulating AgentsProducts: MYLOTARG POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 5MG/VIAL